Advantages of RPP PCR Testing
Respiratory Pathogen Panel (RPP) PCR testing provides rapid, highly accurate detection of multiple respiratory pathogens from a single sample. It offers major clinical advantages over traditional testing methods such as culture, antigen testing, or single-target PCR.
1. Rapid, Same-Day Results
RPP delivers results in hours, enabling clinicians to quickly identify the cause of respiratory symptoms and start appropriate treatment without delay.
2. Detects a Wide Range of Pathogens at Once
A comprehensive RPP simultaneously tests for viruses, bacteria, and atypical organisms—including influenza, RSV, adenovirus, rhinovirus, SARS-CoV-2, Mycoplasma, and others.
This broad coverage ensures no major respiratory pathogen is overlooked.
3. High Sensitivity and Specificity
RPP PCR can detect very low levels of viral or bacterial genetic material, making it far more accurate than rapid antigen testing and traditional culture methods.
4. Identifies Co-Infections
Many patients may have multiple pathogens driving symptoms. RPP uniquely detects co-infections, which are often missed by single-target tests and can influence treatment decisions.
5. Guides Proper Treatment and Reduces Antibiotic Misuse
By identifying whether a patient has a viral vs. bacterial infection, RPP helps clinicians prescribe the right therapy and avoid unnecessary antibiotics.
6. Essential for High-Risk Populations
RPP is particularly valuable for:
- children and elderly patients
- immunocompromised individuals
- patients with chronic lung disease
- hospitalized or ICU patients
The accuracy and speed of RPP significantly improve management and outcomes in these groups.
7. Useful When Symptoms Overlap
Respiratory infections often present with similar symptoms. RPP clarifies whether symptoms are due to influenza, COVID-19, RSV, or other pathogens—critical for proper isolation, treatment, and follow-up.
8. Works Even After Symptom Onset or Partial Treatment
PCR technology can detect pathogens even when viral load is low or when antibiotics/antivirals have already been started, reducing false negatives.
| Viruses | Bacteria | Antibiotic Resistance Targets |
|---|---|---|
| Influenza A | Coxiella burnetii | PVL (Panton-Valentine leukocidin) |
| Influenza B | Pneumocystis jirovecii | mecA (Methicillin resistance in Staphylococcus aureus) |
| Human Respiratory Syncytial Virus A | Moraxella catarrhalis | van A/B (Vancomycin resistance |
| Human Respiratory Syncytial Virus B | Klebsiella pneumoniae | |
| Influenza C | Streptococcus pneumoniae | |
| Influenza A/H3 | Mycoplasma pneumoniae | |
| Influenza A/H1-2009 | Chlamydia pneumoniae | |
| Human Coronavirus OC43 | Legionella longbeach | |
| Human Coronavirus 229E | Legionella pneumophila | |
| Human Coronavirus NL63 | Haemophilus influenzae | |
| Human Coronavirus HKU1 | Haemophilus influenzae B | |
| Parainfluenza Virus 1 | Bordetella parapertussis | |
| Parainfluenza Virus 2 | Bordetella pertussis | |
| Parainfluenza Virus 3 | Bordetella holmesii | |
| Parainfluenza Virus 4 | Group A Strep | |
| Human enterovirus | Group B Strep | |
| Human metapneumovirus A/B | Group C & G Strep | |
| MERS | Staphylococcus aureus | |
| SARS | ||
| Human bocavirus | ||
| Human rhinovirus | ||
| Human parechovirus | ||
| Human adenovirus 3 |
